Progress report: familial pancreatic cancer

Area of Science:

• Oncology
• Genetics
• Gastroenterology

Background:

• Hereditary predisposition accounts for approximately 5% of pancreatic ductal adenocarcinoma (PDAC) cases.
• Familial pancreatic cancer (FPC) represents the majority of hereditary PDAC.
• FPC is defined by specific family history criteria for PDAC without other known inherited tumor syndromes.

Purpose of the Study:

• To provide a progress report on familial pancreatic cancer (FPC).
• To summarize recent advancements (last 5 years) in FPC.
• To cover molecular pathogenesis, diagnosis, surveillance, and treatment of FPC.

Main Methods:

• Literature review of studies published in the last 5 years.
• Synthesis of information on molecular pathogenesis.
• Compilation of data on clinical and molecular diagnosis, surveillance strategies, and novel treatment options.

Main Results:

• Recent progress in understanding the molecular underpinnings of FPC.
• Updates on diagnostic approaches, including genetic and clinical methods.
• Emerging surveillance protocols and novel therapeutic strategies for FPC patients.

Conclusions:

• Significant advancements have been made in FPC research over the past 5 years.
• Improved understanding of molecular pathogenesis aids diagnosis and treatment.
• Ongoing research continues to refine surveillance and develop new therapies for hereditary pancreatic cancer.